Johnson & Johnson reported Phase 3 MonumenTAL-6 study results for multiple myeloma treatment.
The combination of bispecific antibodies Tecvayli and Talvey reduced the risk of disease progression or death by 89% compared to the standard of care.
The regimen also demonstrated a 62% reduction in the risk of death.
The trial evaluated patients with relapsed or refractory multiple myeloma who had received one to four prior lines of therapy.
An independent data monitoring committee recommended unblinding the trial early based on the positive findings.
The chemotherapy-free combination could establish a new standard of care for earlier treatment stages.
Johnson & Johnson plans to present full results at a future medical meeting and share data with global health authorities.